The Transcription Factor Mrr1p Controls Expression of the MDR1 Efflux Pump and Mediates Multidrug Resistance in Candida albicans
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Constitutive overexpression of the MDR1 (multidrug resistance) gene, which encodes a multidrug efflux pump of the major facilitator superfamily, is a frequent cause of resistance to fluconazole and other toxic compounds in clinical Candida albicans strains, but the mechanism of MDR1 upregulation has not been resolved. By genome-wide gene expression analysis we have identified a zinc cluster transcription factor, designated as MRR1 (multidrug resistance regulator), that was coordinately upregulated with MDR1 in drug-resistant, clinical C. albicans isolates. Inactivation of MRR1 in two such drug-resistant isolates abolished both MDR1 expression and multidrug resistance. Sequence analysis of the MRR1 alleles of two matched drug-sensitive and drug-resistant C. albicans isolate pairs showed that the resistant isolates had become homozygous for MRR1 alleles that contained single nucleotide substitutions, resulting in a P683S exchange in one isolate and a G997V substitution in the other isolate. Introduction of these mutated alleles into a drug-susceptible C. albicans strain resulted in constitutive MDR1 overexpression and multidrug resistance. By comparing the transcriptional profiles of drug-resistant C. albicans isolates and mrr1Delta mutants derived from them and of C. albicans strains carrying wild-type and mutated MRR1 alleles, we defined the target genes that are controlled by Mrr1p. Many of the Mrr1p target genes encode oxidoreductases, whose upregulation in fluconazole-resistant isolates may help to prevent cell damage resulting from the generation of toxic molecules in the presence of fluconazole and thereby contribute to drug resistance. The identification of MRR1 as the central regulator of the MDR1 efflux pump and the elucidation of the mutations that have occurred in fluconazole-resistant, clinical C. albicans isolates and result in constitutive activity of this trancription factor provide detailed insights into the molecular basis of multidrug resistance in this important human fungal pathogen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Construction of mrr1Δ Mutants and Complemented Strains (A) Structure of the deletion cassette from plasmid pZCF36M2 (top), which was used to delete the MRR1 ORF in strains SC5314, F5, G5, and CAG48B, and genomic structure of the MRR1 locus in the parental strains (bottom). The MRR1 coding region is represented by the white arrow and the upstream and downstream regions (5′MRR1 and 3′MRR1) by the solid lines. The SAT1 flipper cassette (SAT1-FLIP), in which the caFLP gene is expressed from the inducible SAP2 promoter [30], is represented by the grey rectangle bordered by FRT sites (black arrows). The 34 bp FRT sites are not drawn to scale. The probes used for Southern hybridization analysis of the mutants are indicated by the black bars. (B) Structure of the DNA fragments from plasmids pZCF36K2, pZCF36K3, pZCF36K4, and pZCF36K5 (top), which were used for integration the MRR1 F2–1, MRR1 F5, MRR1 G2–2, and MRR1 G5 alleles, respectively, into the disrupted mrr1 locus of homozygous and heterozygous mrr1Δ mutants (bottom) using the caSAT1 selection marker (grey arrow). TACT1, transcription termination sequence of the ACT1 gene. Only relevant restriction sites are given in (A) and (B): A, ApaI; B, BglII; E, EcoRI; N, NsiI; Nd, NdeI; P, PstI; S, SalI; ScI, SacI; ScII, SacII; X, XhoI. The PstI and NsiI sites shown in parenthesis were destroyed by the cloning procedure. (C) Southern hybridization of NsiI-digested genomic DNA of mrr1Δ mutants derived from strain SC5314 and of strains with reinserted MRR1 alleles with the MRR1-specific probe 1. The sizes of the hybridizing fragments (in kb) are given on the left side of the blot and their identities are indicated on the right. The genotype of the strains is given above the respective lanes. Only one of the two independently constructed series of strains is shown. Inactivation of MRR1 in the clinical isolates F5 and G5 and the reporter strain CAG48B and reinsertion of different MRR1 alleles in mrr1 mutants of the reporter strain occurred in an analogous fashion.](https://figures.cochat.ai/paper-figures/92ad36a1a1ee4d74832061200ec93001/the-transcription-factor-mrr1p-controls-expression-of-the-mdr1-efflux-pump-and-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mutual dependence of Mrr1 and Snf2 occupancy at the MDR1 promoter is consistent with their requirements for MDR1 transcriptional activation (17) (Fig. 1).”
From Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperactivation of Mrr1 by xenobiotics and the subsequent expression of MDR1 play a key role in detoxifying compounds such as benomyl (17, 19–21).”
From Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, deletion of MRR1 in each MDR1-overexpressing isolate did not yield identical MICs to strains lacking MDR1 in the same background.”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of MDR1 is the major, but not the exclusive, fluconazole resistance pathway in strains with MRR1GOF mutations (17, 19).”
From Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MRR1GOF mutations induce drug efflux gene expression and are commonly found in fluconazole-resistant C. albicans clinical isolates (1, 2, 17, 18).”
From Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance (2017) · cites this paper as [17]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353 · cited 1×
“candidiasis, which frequently affects HIV-infected persons and AIDS patients [2].”
BackgroundA rapid and simple method for preparation of RNA from Saccharomyces cerevisiae
Schmitt, M. E., Brown, T. A., & Trumpower, B. L. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.10.3091 · Cited by 1,338 · cited 1×
“Total RNA was isolated using the hot SDS-phenol method [52].”
MethodSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“years ago [3], many studies have shown that the major mechanism of resistance to the widely used antifungal agent fluconazole in clinical C.”
BackgroundThe SAT1 flipper, an optimized tool for gene disruption in Candida albicans
Reuß, O., Vik, Å., Kolter, R., & Morschhäuser, J. (2004) · Gene · doi:10.1016/j.gene.2004.06.021 · Cited by 742
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 2×
“isolates from the same patient, so-called matched isolates, have proved an excellent tool to study the molecular basis of drug resistance [3–10].”
MethodSanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Prasad, R., De Wergifosse, P., Goffeau, A., & Balzi, E. (1995) · Current Genetics · doi:10.1007/bf00352101 · Cited by 486
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 2×
“isolates from the same patient, so-called matched isolates, have proved an excellent tool to study the molecular basis of drug resistance [3–10].”
MethodSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465 · cited 1×
“isolates from the same patient, so-called matched isolates, have proved an excellent tool to study the molecular basis of drug resistance [3–10].”
MethodCoste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407 · cited 8×
“Two main factors, namely 1) the discovery of a cis-regulatory element in the promoters of CDR1 and CDR2 with features that are typical of binding sites of zinc cluster transcription factors, and 2) the observation that homozygosity at the mating type locus was linked with the development of azole resistance in certain…”
BackgroundInfluential
Research works printed but not linked: 1
- OddsFC 1988 Candida and candidosis: a review and bibliography London Bailliere Tindall
Cited by
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“MRR1, multidrug resistance regulator 1, was identified by comparing the transcriptomes of sets of matched isolates in which the fluconazole-resistant isolates overexpressed MDR1 (Morschhäuser et al., 2007).”
BackgroundSelf-citationAntifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“Genome-wide transcriptional studies using clinical strains revealed a core set of 14 genes involved in diverse functions that are up-regulated in isolates carrying MRR1 GOF mutations (Morschhauser et al. 2007).”
BackgroundSelf-citationEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
“In some instances, FLC-resistant clinical isolates overexpress the MFS transporter CaMdr1p (232).”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
“ways in addition to drug transporters (341, 391).”
BackgroundFluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
“by the transcription factor Mrr1p, and point mutations within this factor induce overexpression of its target gene.(82) There”
BackgroundAntifungal drug resistance: evolution, mechanisms and impact
Revie, N. M., Iyer, K. R., Robbins, N., & Cowen, L. E. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.02.005 · Cited by 516
Antifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
“Genome-wide transcriptional analyses of clinical isolates that exhibit MDR1upregulation permitted the identification of a Zn2-Cys6 transcription factor that is coregulated with MDR1 [179].”
BackgroundCandidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
“The efflux pumps CaCDR1 and CaCDR2 are regulated by transcription factor CaTac1p, while CaMDR1 is regulated by transcription factor CaMrr1p [48,49].”
BackgroundMolecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441
Kretschmer, M., Leroch, M., Mosbach, A., Walker, A.-S., Fillinger, S., Mernke, D., Schoonbeek, H.-J., Pradier, J.-M., Leroux, P., De Waard, M. A., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000696 · Cited by 419
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
“In C. albicans, CDR1 and CDR2 are known to be regulated 5 Sanglard Antifungal Resistance in Fungal Pathogens Frontiers in Medicine | www.frontiersin.org March 2016 | Volume 3 | Article 11 by a zinc cluster finger transcriptional regulator called TAC1 and MDR1 by another regulator called MRR1 (48, 49).”
Backgroundde Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
“Thus, the main research targets include the CDR1, CDR2, and MDR1 genes (Puri et al., 1999; Yang and Lo, 2001; Morschhäuser et al., 2007; Tsao et al., 2009).”
BackgroundCandida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Regulation of multidrug resistance in pathogenic fungi
Morschhäuser, J. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.08.002 · Cited by 300
Self-citationSanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285
“Similar to CDR1/2 upregulation by Tac1, MDR1 overexpression is also caused by GOF mutations in its regulator, Mrr1 (Morschhauser et al., 2007).”
BackgroundResultInfluentialStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Dunkel, N., Blaß, J., Rogers, P. D., & Morschhäuser, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06309.x · Cited by 278
“…in this isolate (see above and Discussion), and the strong effect of deletion of the MRR1 T896I allele on fluconazole resistance in isolate DSY2286 could be explained by strain-specific differences in other Mrr1p target genes that contribute to fluconazole resistance (Morschhäuser et al., 2007).”
BackgroundMethodResultSelf-citationRosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239
“As seen with TAC1 or MRR1 mutations, a loss-of-heterozygosity event that results in two GOF alleles, either by a mitotic recombination event between homologous chromosomes or by a loss of a chromosome combined with a duplication of the homologous chromosome, would provide an advantage when challenged with antifungals…”
BackgroundMethodResultInfluentialSelf-citationDunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236
“In all cases examined so far, overexpression of the ABC transporters CDR1 and CDR2 is caused by gain-of-function mutations in the transcription factor Tac1p (5, 6, 49), overexpression of the major facilitator MDR1 is caused by gain-offunction mutations in Mrr1p (31), and as shown here, overexpression of ERG11 is cause…”
BackgroundSelf-citationEfflux in Fungi: La Pièce de Résistance
Coleman, J. J., & Mylonakis, E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000486 · Cited by 234
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“Resistance to azoles in C. parapsilosis has been attributed to mutations in the transcription factor gene MRR1 [84] and ERG11 (Y132F, either alone or in combination with an R398I) [85–87], and overexpression of CDR1, MDR1, and ERG11 [85,86,88].”
BackgroundInfluentialCosta-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
“The multidrug resistant regulator, Mrr1, is the transcription factor that controls the expression and is upregulated with MDR1 in drug resistant clinical isolates [55,71].”
BackgroundReview on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris
Chaabane, F., Graf, A., Jequier, L., & Coste, A. T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02788 · Cited by 223
“Enhanced overexpression of efflux pumps is one of the major resistance mechanism to azoles in pathogenic Candida species (Schuetzer-Muehlbauer et al., 2003; Morschhäuser et al., 2007).”
BackgroundMechanisms of Antifungal Properties of Metal Nanoparticles
Slavin, Y. N., & Bach, H. (2022) · Nanomaterials · doi:10.3390/nano12244470 · Cited by 198
“This can arise due to many mechanisms, including gene upregulation [129] for cell wall component synthesis [130] or efflux pump synthesis [131], modification of target site [132], or development of biofilm [133], amongst others.”
BackgroundSchwarzmüller, T., Ma, B., Hiller, E., Istel, F., Tscherner, M., Brunke, S., Ames, L., Firon, A., Green, B., Cabral, V., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004211 · Cited by 191
Polke, M., Hube, B., & Jacobsen, I. D. (2015) · Advances in Applied Microbiology · doi:10.1016/bs.aambs.2014.12.002 · Cited by 184
Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 180
“Efflux pump overexpression can be further induced by upstream GOF mutations, regulating transcription factor genes (Table 3) [59,125–130, 144, 145].”
BackgroundEpidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus
Gonçalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F., & Colombo, A. L. (2016) · Mycoses · doi:10.1111/myc.12469 · Cited by 180
Update on Antifungal Drug Resistance
Perlin, D. S., Shor, E., & Zhao, Y. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0015-1 · Cited by 174
A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
Kidd, S. E., Chen, S. C.-A., Meyer, W., & Halliday, C. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02903 · Cited by 166
Oropharyngeal candidiasis in the era of antiretroviral therapy
Thompson, G. R., Patel, P. K., Kirkpatrick, W. R., Westbrook, S. D., Berg, D., Erlandsen, J., Redding, S. W., & Patterson, T. F. (2010) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2009.11.026 · Cited by 164
Holmes, A. R., Lin, Y.-H., Niimi, K., Lamping, E., Keniya, M., Niimi, M., Tanabe, K., Monk, B. C., & Cannon, R. D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00463-08 · Cited by 159
“Mediators of azole efflux from C. albicans include the major facilitator superfamily pumps Mdr1p (28) and Flu1p (1) and the ATPbinding cassette (ABC) transporters Cdr1p and Cdr2p (4, 52).”
BackgroundShih, P.-Y., Liao, Y.-T., Tseng, Y.-K., Deng, F.-S., & Lin, C.-H. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00602 · Cited by 156
Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 164
Branco, J., Miranda, I. M., & Rodrigues, A. G. (2023) · Journal of Fungi · doi:10.3390/jof9010080 · Cited by 164
Heilmann, C. J., Schneider, S., Barker, K. S., Rogers, P. D., & Morschhäuser, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-09 · Cited by 142
“Tac1p (transcriptional activator of CDR genes) controls expression of the ATP-binding cassette (ABC) transporters CDR1 and CDR2, whereas Mrr1p (multidrug resistance regulator) regulates expression of the MDR1 gene encoding an efflux pump of the major facilitator superfamily (3, 12).”
BackgroundResultSelf-citationAbrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris
Rybak, J. M., Doorley, L. A., Nishimoto, A. T., Barker, K. S., Palmer, G. E., & Rogers, P. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00057-19 · Cited by 141
“albicans MDR1 is known to be an effector of triazole resistance (14).”
BackgroundSelf-citationExpandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138
Multidrug resistance in fungi: regulation of transporter-encoding gene expression
Paul, S., & Moye-Rowley, W. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00143 · Cited by 137
Schubert, S., Barker, K. S., Znaidi, S., Schneider, S., Dierolf, F., Dunkel, N., Aïd, M., Boucher, G., Rogers, P. D., Raymond, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01343-10 · Cited by 135
“ClaI-digested pZCF36K2 (23) to obtain pZCF36H2, in which the 3 HA-tagged”
BackgroundMethodSelf-citationMolecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals
Eddouzi, J., Parker, J. E., Vale-Silva, L. A., Coste, A., Ischer, F., Kelly, S., Manai, M., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-13 · Cited by 128
“albicans isolates can develop resistance to azole drugs by various mechanisms, including the overexpression of efflux pump membrane proteins, which actively transport antifungal drugs out of the cell (1, 18, 19, 28), or mutations in the target enzyme, decreasing its affinity to azoles (15, 23).”
BackgroundTsao, S., Rahkhoodaee, F., & Raymond, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00926-08 · Cited by 126
“Similarly, gain-of-function mutations in two other zinc cluster transcription factors, Mrr1p and Upc2p, have recently been shown to be responsible for the constitutive upregulation of Mdr1p and Erg11p, respectively, in clinical Ar isolates (10, 22 ).”
BackgroundTrichophyton rubrum Azole Resistance Mediated by a New ABC Transporter, TruMDR3
Monod, M., Feuermann, M., Salamin, K., Fratti, M., Makino, M., Alshahni, M. M., Makimura, K., & Yamada, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00863-19 · Cited by 116
Znaidi, S., Weber, S., Zin Al-Abdin, O., Bomme, P., Saidane, S., Drouin, S., Lemieux, S., De Deken, X., Robert, F., & Raymond, M. (2008) · Eukaryotic Cell · doi:10.1128/ec.00070-08 · Cited by 119
“It was shown previously that the constitutive overexpression of CDR1, CDR2, and PDR16 in azole-resistant isolates is due to gain-of-function mutations in the transcription factor Tac1p (11, 12, 59) and that MDR1 overexpression is the consequence of activating mutations in Mrr1p (31).”
BackgroundInfluentialMorschhäuser, J. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5628-4 · Cited by 118
Self-citationCastanheira, M., Deshpande, L. M., Davis, A. P., Rhomberg, P. R., & Pfaller, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00906-17 · Cited by 114
“Relative quantification of target genes was performed in triplicate by normalization to the level of an endogenous reference gene (the 18S rRNA gene) on a StepOne Plus instrument (Life Technologies, Carlsbad, CA, USA) using custom-designed or previously published (38) primers showing 97.”
MethodIdentification of the Candida albicans Cap1p Regulon
Znaidi, S., Barker, K. S., Weber, S., Alarco, A.-M., Liu, T. T., Boucher, G., Rogers, P. D., & Raymond, M. (2009) · Eukaryotic Cell · doi:10.1128/ec.00002-09 · Cited by 115
“A study with S. cerevisiae also showed that a subset of OSR genes was upregulated rapidly after the addition of benomyl (39).”
BackgroundInfluentialSelf-citationLemos, A. S. D. O., Florêncio, J. R., Pinto, N. D. C. C., Campos, L. M., Silva, T. P. D., Grazul, R. M., Pinto, P. D. F., Tavares, G. D., Scio, E., Apolônio, A. C. M., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01525 · Cited by 122
Contribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110
“albicans) have concluded to a convergence of transcriptional profiles with different mutations on a same regulator [22,23,24].”
BackgroundResistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Fungal Drug Response and Antimicrobial Resistance
Osset-Trénor, P., Pascual‐Ahuir, A., & Proft, M. (2023) · Journal of Fungi · doi:10.3390/jof9050565 · Cited by 117
Hoehamer, C. F., Cummings, E. D., Hilliard, G. M., & Rogers, P. D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00756-09 · Cited by 100
“251, which are proteins whose genes were previously shown to be associated with azole resistance (30).”
BackgroundInfluentialSelf-citationAntifungal Drug Discovery: The Process and Outcomes
Calderone, R., Sun, N., Gay-Andrieu, F., Groutas, W., Weerawarna, P., Prasad, S., Alex, D., & Li, D. (2014) · Future Microbiology · doi:10.2217/fmb.14.32 · Cited by 97
Elucidating Drug Resistance in Human Fungal Pathogens
Xie, J. L., Polvi, E. J., Shekhar-Guturja, T., & Cowen, L. E. (2014) · Future Microbiology · doi:10.2217/fmb.14.18 · Cited by 100
Nishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Self-citationArastehfar, A., Daneshnia, F., Hafez, A., Khodavaisy, S., Najafzadeh, M.-J., Charsizadeh, A., Zarrinfar, H., Salehi, M., Shahrabadi, Z. Z., Sasani, E., et al. (2020) · Medical Mycology · doi:10.1093/mmy/myz124 · Cited by 99
MacCallum, D. M., Coste, A., Ischer, F., Jacobsen, M. D., Odds, F. C., & Sanglard, D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-09 · Cited by 98
“Another study inactivated MRR1, a regulator of MDR1, in the same isolates, which also resulted in strains with intermediate azole resistance (17).”
BackgroundBerkow, E. L., Manigaba, K., Parker, J. E., Barker, K. S., Kelly, S. L., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01358-15 · Cited by 95
“albicans, in which the deletion of CaMDR1 in resistant isolates overexpressing this gene led to only a 1-dilution decrease in fluconazole susceptibility (14).”
BackgroundSelf-citationBezerra, A. R., Simões, J., Lee, W., Rung, J., Weil, T., Gut, I. G., Gut, M., Bayés, M., Rizzetto, L., Cavalieri, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302094110 · Cited by 110
“Proc Natl Acad Sci USA 105(43):16502–16507.”
BackgroundInfluentialSasse, C., Dunkel, N., Schäfer, T., Schneider, S., Dierolf, F., Ohlsen, K., & Morschhäuser, J. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08210.x · Cited by 93
“The constitutive activity of Mrr1 and Tac1 results in the upregulation of additional target genes of these transcription factors, which also contribute to drug resistance (Coste et al., 2004; Liu et al., 2007; Morschhäuser et al., 2007; Znaidi et al., 2007; Schubert et al., 2011).”
BackgroundSelf-citationRole of Ndt80p in Sterol Metabolism Regulation and Azole Resistance in Candida albicans
Sellam, A., Tebbji, F., & Nantel, A. (2009) · Eukaryotic Cell · doi:10.1128/ec.00074-09 · Cited by 91
“(32) have elucidated a mechanism that results in the overexpression of MDR1 in clinical isolates.”
BackgroundChang, W., Liu, J., Zhang, M., Shi, H., Zheng, S., Jin, X., Gao, Y., Wang, S., Ji, A., & Lou, H. (2018) · Nature Communications · doi:10.1038/s41467-018-07633-9 · Cited by 91
Drug resistance mechanisms and their regulation in non-albicans Candida species
Kołaczkowska, A., & Kołaczkowski, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv445 · Cited by 87
The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility
Yan, L., Li, M., Cao, Y., Gao, P., Cao, Y., Wang, Y., & Jiang, Y. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp273 · Cited by 89
Nucleic acid therapeutics: basic concepts and recent developments
Sharma, V. K., Rungta, P., & Prasad, A. K. (2014) · RSC Advances · doi:10.1039/c3ra47841f · Cited by 91
Lohberger, A., Coste, A. T., & Sanglard, D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00245-13 · Cited by 85
“Control of MDR1 expression was shown to involve the transcriptional activator MRR1 (for multidrug resistance regulator) (15).”
BackgroundSellam, A., Askew, C., Epp, E., Lavoie, H., Whiteway, M., & Nantel, A. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-11-1093 · Cited by 87
“Recent work elucidated the mechanism controlling the overexpression of MDR1 and multidrug resistance in those clinical isolates (Morschhauser et al., 2007).”
What do we know about the biology of the emerging fungal pathogen of humans Candida auris?
Bravo Ruiz, G., & Lorenz, A. (2021) · Microbiological Research · doi:10.1016/j.micres.2020.126621 · Cited by 85
Bing, J., Hu, T., Zheng, Q., Muñoz, J. F., Cuomo, C. A., & Huang, G. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01466-20 · Cited by 86
Transcriptional profiling of azole-resistant Candida parapsilosis strains
Silva, A. P., Miranda, I. M., Guida, A., Synnott, J., Rocha, R., Silva, R., Amorim, A., Pina-Vaz, C., Butler, G., & Rodrigues, A. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01127-10 · Cited by 86
“The resistant strains obtained after exposure to fluconazole and to voriconazole have increased expression of the transcription factor MRR1, the major facilitator transporter MDR1, and several reductases and oxidoreductases.”
BackgroundInfluentialSchillig, R., & Morschhäuser, J. (2013) · Molecular Microbiology · doi:10.1111/mmi.12327 · Cited by 85
“In fact, the identification of gain-of-function mutations in Mrr1 and Tac1 was crucial for the elucidation of their roles in drug resistance (Coste et al., 2004; Morschhäuser et al., 2007).”
BackgroundMethodSelf-citationThe effect of biomaterials and antifungals on biofilm formation by Candida species: a review
Cuéllar‐Cruz, M., Vega‐González, A., Mendoza‐Novelo, B., López-Romero, E., Ruiz‐Baca, E., Escorza, M. A. Q., & Villagómez-Castro, J. C. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1634-6 · Cited by 102
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Novel ERG11 and TAC1b Mutations Associated with Azole Resistance in Candida auris
Li, J., Coste, A. T., Liechti, M., Bachmann, D., Sanglard, D., & Lamoth, F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02663-20 · Cited by 82
Gehesquière, B., Crouch, J. A., Marra, R. E., Poucke, K. V., Rys, F., Maes, M., Gobin, B., Höfte, M., & Heungens, K. (2015) · Plant Pathology · doi:10.1111/ppa.12401 · Cited by 87
Chemogenomic profiling predicts antifungal synergies
Jansen, G., Lee, A. Y., Epp, E., Fredette, A., Surprenant, J., Harcus, D., Scott, M., Tan, E., Nishimura, T., Whiteway, M., et al. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.95 · Cited by 80
“Dunkel et al , 2008 ), or increased the expression of a multi-drug efflux pump ( MDR1 , strain G5”
BackgroundNeji, S., Hadrich, I., Trabelsi, H., Abbes, S., Cheikhrouhou, F., Sellami, H., Makni, F., & Ayadi, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0376-2 · Cited by 73
“albicans, upregulation of MRR1 may be caused by single gain-of-function mutations [18, 33].”
BackgroundJin, X., Zhang, M., Lu, J., Duan, X., Chen, J., Liu, Y., Chang, W., & Lou, H. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.016 · Cited by 75
The effect of antifungal resistance development on the virulence of Candida species
Bohner, F., Papp, C., & Gácser, A. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac019 · Cited by 78
“Prominent presence of efflux pumps in the cellular membrane leads to a more effective elimination of the antifungals from the cytoplasm, which results in less azole susceptible cells (Morschhäuser et al. 2007, Robbins et al. 2017).”
Schubert, S., Rogers, P. D., & Morschhäuser, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00740-08 · Cited by 74
“vector pBC, has been described previously (21).”
BackgroundSelf-citationFluconazole-resistant Candida parapsilosis: A new emerging threat in the fungi arena
Escribano, P., & Guinea, J. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.1010782 · Cited by 74
“involves the presence of mutations in the TAC1 (transcriptional activator of CDR genes) and MRR1 (transcription factor and multidrug resistance regulator) genes, which lead to overexpression of CDR and MDR1, respectively, resulting in the pumping of fluconazole out of the cell (Morschhauser et al., 2007; Liu and Myers…”
BackgroundSang, H., Hulvey, J., Popko, J. T., Lopes, J. M., Swaminathan, A., Chang, T., & Jung, G. (2014) · Molecular Plant Pathology · doi:10.1111/mpp.12174 · Cited by 80
“In the human pathogenic fungus, Candida albicans, an MDR phenotype is routinely reported, when prolonged treatments of the DMI fungicide fluconazole can select for strains showing constitutive over-expression of the PDR transporters CDR1 and CDR2 (Morschhäuser et al., 2007).”
BackgroundUPC2 Is Universally Essential for Azole Antifungal Resistance in Candida albicans
Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S., & Rogers, P. D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00221-13 · Cited by 71
Self-citationIyer, K. R., Camara, K., Daniel-Ivad, M., Trilles, R., Pimentel-Elardo, S. M., Fossen, J. L., Marchillo, K., Liu, Z., Singh, S., Muñoz, J. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20183-3 · Cited by 72
Chitosan-Based Drug Delivery Systems for Optimization of Photodynamic Therapy: a Review
Calixto, G. M. F., de Annunzio, S. R., Victorelli, F. D., Frade, M. L., Ferreira, P. S., Chorilli, M., & Fontana, C. R. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1407-y · Cited by 75
Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Candida Pathogens
Sharma, J., Rosiana, S., Razzaq, I., & Shapiro, R. S. (2019) · Journal of Fungi · doi:10.3390/jof5010017 · Cited by 65
Magobo, R. E., Lockhart, S. R., & Govender, N. P. (2020) · Mycoses · doi:10.1111/myc.13070 · Cited by 73
Abbey, D., Hickman, M., Gresham, D., & Berman, J. (2011) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.111.000885 · Cited by 64
“For example, homozygosis of hyperactive alleles of several genes ( e.g. ERG11 , TAC1 , and MRR1) signi fi cantly enhances the ability of C. albicans to grow in the presence of fl uconazole (Coste et al. 2007; Morschhauser et al. 2007; White et al. 2002).”
MFS transporters of Candida species and their role in clinical drug resistance
Redhu, A. K., Shah, A. H., & Prasad, R. (2016) · FEMS Yeast Research · doi:10.1093/femsyr/fow043 · Cited by 72
“These gain of function mutant variants of Mrr1 are able to activate MDR1 expression even in drug susceptible clinical isolates (Morschhauser et al. 2007; Dunkel et al. 2008a).”
BackgroundZou, Z., Zou, R., Zong, D., Shi, Y., Chen, J., Huang, J., Zhu, J., Chen, L., Bao, X., Liu, Y., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13114 · Cited by 69
“Enzymes, anti-apoptotic genes and DNA repair mechanisms reportedly contribute to MDR [3, 4].”
BackgroundSiikala, E., Rautemaa, R., Richardson, M., Saxen, H., Bowyer, P., & Sanglard, D. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq354 · Cited by 66
Chen, L., Xu, Y., Zhou, C., Zhao, J., Li, C., & Wang, R. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800216 · Cited by 66
Exploitation of genomics in fungicide research: current status and future perspectives
Cools, H. J., & Hammond-Kosack, K. E. (2012) · Molecular Plant Pathology · doi:10.1111/mpp.12001 · Cited by 69
“sion of MDR1, as well as genes involved in the regulation of the cellular redox state (Karababa et al., 2004; Morschhauser et al., 2007).”
BackgroundMedically Important Fungi Respond to Azole Drugs: An Update
Zavřel, M., & White, T. C. (2015) · Future Microbiology · doi:10.2217/fmb.15.47 · Cited by 69
Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae
Kannan, A., Asner, S. A., Trachsel, E., Kelly, S., Parker, J., & Sanglard, D. (2019) · mBio · doi:10.1128/mbio.02512-19 · Cited by 63
“albicans, this protein is known as a regulator of MDR1, a major facilitator efflux transporter that mediates FLC resistance (20).”
BackgroundNew antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
Metadata
- Authors
- Morschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D.
- Affiliations
- University of Würzburg (DE)
- University of Tennessee Health Science Center (US)
- University of Memphis (US)
- Corresponding author
- Morschhäuser, Joachim
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-11-02
- Volume
- 3
- Issue
- 11
- Pages
- e164
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2048531
- OpenAlex
- W2008837893
- Cited by
- 355
- References
- 51
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 17 · 2023: 22 · 2022: 18 · 2021: 18 · 2020: 23 · 2019: 32 · 2018: 14 · 2017: 25 · 2016: 14 · 2015: 13 · 2014: 22 · 2013: 15 · 2012: 16
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (SFB 630, MO 846/3)
- National Institutes of Health (AI058145)
- National Institute of Allergy and Infectious Diseases (R01AI058145, AI058145, R21AI058145)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- MRR1, MDR1, multidrug resistance, Candida albicans, fluconazole resistance, transcription factors, efflux pumps, zinc cluster transcription factors, oxidative enzymes, drug resistance mutations, gene expression regulation, antifungal resistance
- MeSH terms
- Antifungal Agents, Base Sequence, Candida albicans, Flow Cytometry, Humans, Molecular Sequence Data, Mutation, Transcription Factors, Blotting, Southern, Fluconazole, Gene Expression, Gene Expression Regulation, Fungal, In Situ Hybridization, Genes, MDR, Reverse Transcriptase Polymerase Chain Reaction, ATP Binding Cassette Transporter, Subfamily B, Member 1, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Drug Resistance, Multiple, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.